PMID- 8884162
OWN - NLM
STAT- MEDLINE
DCOM- 19970108
LR  - 20181113
IS  - 0114-5916 (Print)
IS  - 0114-5916 (Linking)
VI  - 15
IP  - 2
DP  - 1996 Aug
TI  - Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy').
PG  - 107-15
AB  - 3,4-Methylenedioxymethamphetamine (MDMA; 'ecstasy') is an increasingly popular 
      recreational drug in the US, Western Europe and Australia. In animals, including 
      nonhuman primates, MDMA is known to damage brain serotonin (5-hydroxytryptamine; 
      5-HT) neurons. It is not known whether MDMA damages serotonin neurons in the 
      human brain but there is some indication that it may. Although the large majority 
      of individuals who have used MDMA recreationally do not develop acute 
      complications, as the popularity of MDMA has increased, so have reports of 
      adverse nonpsychiatric and psychiatric consequences associated with use of the 
      drug. Further, since manifestations of MDMA-induced serotonin injury might only 
      become apparent with age, or under periods of stress, it is possible that some 
      individuals with no apparent abnormalities might develop complications over time.
FAU - McCann, U D
AU  - McCann UD
AD  - Unit on Anxiety Disorders, National Institute of Mental Health, Bethesda, 
      Maryland, USA.
FAU - Slate, S O
AU  - Slate SO
FAU - Ricaurte, G A
AU  - Ricaurte GA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drug Saf
JT  - Drug safety
JID - 9002928
RN  - 0 (Hallucinogens)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Brain/drug effects
MH  - Hallucinogens/*adverse effects
MH  - Heart/drug effects
MH  - Humans
MH  - Mental Disorders/chemically induced
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*adverse effects
MH  - Substance-Related Disorders
RF  - 88
EDAT- 1996/08/01 00:00
MHDA- 1996/08/01 00:01
CRDT- 1996/08/01 00:00
PHST- 1996/08/01 00:00 [pubmed]
PHST- 1996/08/01 00:01 [medline]
PHST- 1996/08/01 00:00 [entrez]
AID - 10.2165/00002018-199615020-00003 [doi]
PST - ppublish
SO  - Drug Saf. 1996 Aug;15(2):107-15. doi: 10.2165/00002018-199615020-00003.